Heartworm’s Bacterial Partner Lingers After Doxycycline Therapy in Brazilian Dogs

In the humid municipalities of Rio de Janeiro State, where the mosquito-borne heartworm Dirofilaria immitis circulates among companion dogs, a team of veterinary parasitologists has uncovered a finding that complicates one of the most widely used strategies in heartworm management. Doxycycline, an antibiotic that targets Wolbachia, the obligate bacterial endosymbiont living inside heartworms, is a cornerstone of the so-called slow-kill protocol and of pre-treatment regimens before adulticide therapy. The new study, published in the open-access journal Parasites & Vectors, shows that in a cohort of naturally infected dogs treated with doxycycline alone, genetic material from Wolbachia could still be detected in a subset of animals a full 90 days after the course of therapy ended. The result raises questions about how completely the antibiotic eliminates its bacterial target under real-world field conditions, and what that incompleteness might mean for parasite viability, transmission, and the interpretation of diagnostic tests.

The biological rationale for targeting Wolbachia is well established. These intracellular alpha-proteobacteria are not passive passengers; they are essential partners without which filarial nematodes cannot develop normally, reproduce, or remain viable over the long term. Depleting Wolbachia with tetracycline-class antibiotics such as doxycycline therefore undermines the worm itself, sterilizing adult females, shortening adult lifespan, and reducing the inflammatory pathology associated with dead and dying parasites. Because of these effects, veterinary guidelines commonly recommend doxycycline as an adjunct to melarsomine adulticide treatment and as the central component of slower, less intensive protocols for dogs that cannot tolerate adulticide therapy. The assumption underlying these recommendations is that an adequate doxycycline course reliably drives Wolbachia burdens down to undetectable levels, at least within the circulating microfilariae that are easiest to sample and quantify.

To test that assumption quantitatively, the researchers enrolled microfilaremic, heartworm-positive dogs identified in municipalities within the target areas of Rio de Janeiro State. Owners agreed to blood draws on day 0 and again on days 60 and 90, with a five-day window around each scheduled time point, and to administer doxycycline at 10 milligrams per kilogram twice daily for 28 days. Weekly telephone follow-up calls were used to help ensure that owners maintained the dosing schedule, an important consideration in any field study where incomplete compliance could confound the results. Critically, none of the enrolled dogs received any macrocyclic lactone, the class of preventive drugs that includes ivermectin, milbemycin, and moxidectin, at any point during the study. This design choice isolated the effect of doxycycline alone, which is precisely the scenario about which the least controlled field data exist.

The analytical approach combined classical parasitology with modern molecular quantification. On each experimental day, blood samples were subjected to the modified Knott’s test, the long-standing gold-standard technique for detecting and counting microfilariae, the larval offspring of adult female worms that circulate in the bloodstream. A portion of each sample was retained and frozen at minus 20 degrees Celsius for archival purposes, while the remainder was submitted for digital PCR, a technology that partitions each sample into thousands of microscopic reactions and counts target molecules individually. Digital PCR offers an advantage over conventional quantitative PCR in that it provides absolute counts of DNA copies without the need for standard curves, making it well suited to tracking changes in the ratio of Wolbachia DNA to D. immitis DNA within the same blood sample over time.

Thirty-one microfilaremic dogs completed the study, and 27 of them remained microfilaremic throughout the entire observation period. That persistence of circulating larvae in the vast majority of animals is itself noteworthy, because it confirms that doxycycline monotherapy, at least over a 90-day horizon, does not clear microfilaremia in most naturally infected dogs. The more striking molecular result concerned the endosymbiont. By day 90, Wolbachia had been cleared to undetectable levels in 25 of the 31 dogs, demonstrating that the 10 milligrams per kilogram twice-daily dose was fully effective in those cases and that the treatment protocol, as delivered, was capable of eliminating the symbiont from the circulating parasite population in most animals.

But six dogs told a different story. In these animals, digital PCR remained positive for Wolbachia DNA at the quantitative assessment, indicating that the endosymbiont’s genetic material persisted in the bloodstream months after the antibiotic course had ended. The proportions of Wolbachia relative to D. immitis DNA on days 60 and 90 were significantly lower than on day 0, with a p-value below 0.0001, confirming that the treatment did produce a dramatic overall reduction in the symbiont burden even in these persistent cases. When the researchers compared the day 60 and day 90 proportions directly, however, the difference was not statistically significant, with a p-value of 0.3127. In other words, between day 60 and day 90 the relative Wolbachia burden in the persistent dogs plateaued rather than continuing to decline, suggesting that whatever residual signal remained was not being progressively eliminated during the final month of observation.

The authors are careful about interpretation, and their caution is instructive. They note that the data may reflect the absence of macrocyclic lactone use in the cohort, since these preventive drugs kill microfilariae directly and would be expected to remove the larval population in which residual Wolbachia DNA might reside. Alternatively, dogs carrying higher adult worm burdens might simply harbor more symbiont-containing material than a standard doxycycline course can fully deplete. Yet the team explicitly acknowledges that it is not possible to confidently conclude that these factors entirely underpin the observations. The residual DNA signal could represent dead or dying bacteria whose genetic material has not yet been cleared from host tissues, or it could indicate genuinely surviving Wolbachia in a subset of worms or in a subpopulation of the symbiont itself. Distinguishing between these possibilities matters enormously, because DNA persistence from dead organisms is biologically benign, whereas surviving symbionts could repopulate their hosts once antibiotic pressure is removed.

This ambiguity leads directly to the study’s most important recommendation: further research should investigate whether the persistence is related to a lack of efficacy of doxycycline against certain Wolbachia subpopulations or to other, still unidentified factors. The idea of resistant or tolerant symbiont subpopulations is not far-fetched. Bacteria exposed to bacteriostatic drugs such as tetracyclines can enter low-metabolic states that permit survival, and genetic variation among Wolbachia strains infecting different worm individuals, or even different tissues within a single worm, could produce heterogeneous drug susceptibility. If a subpopulation of Wolbachia can withstand a full standard course of doxycycline, the implications extend beyond this single cohort, potentially affecting the reliability of doxycycline-based protocols in regions where such regimens are the only practical option for infected dogs.

For practicing veterinarians and pet owners, the study’s findings should be read as a call for measured reevaluation rather than alarm. The treatment was demonstrably effective in the majority of dogs, and even in the six persistent animals the symbiont burden fell dramatically and remained suppressed. What the study challenges is the assumption that a standard doxycycline course uniformly and permanently eliminates Wolbachia from every treated animal, particularly when no macrocyclic lactone is administered concurrently. It also highlights the value of digital PCR as a surveillance tool, since conventional microscopy of microfilariae would have revealed nothing about the symbiont status of these animals. As heartworm-endemic regions expand and drug-resistant parasite populations emerge, understanding the durability of the doxycycline-Wolbachia axis becomes increasingly consequential. The Rio de Janeiro cohort, small as it is, provides a quantitative baseline for that conversation and a clear agenda for the studies that must follow.

Subject of Research: Persistence of Wolbachia endosymbiont DNA in heartworm-infected dogs after doxycycline-only treatment

Article Title: Persistence of Wolbachia DNA in Dirofilaria immitis-infected canines after doxycycline-only treatment in Rio de Janeiro State, Brazil

Article References: Carithers, D., Alberigi, B., Scott, F., Mendes-de-Almeida, F., Borges, D., Labarthe, N., Brandão, Y., Cunha, R. S., de Souza Ramos, E. A., Molento, M., Yoon, S., McCall, J., & Harrington, J. (2026). Persistence of Wolbachia DNA in Dirofilaria immitis-infected canines after doxycycline-only treatment in Rio de Janeiro State, Brazil. Parasites & Vectors. https://doi.org/10.1186/s13071-026-07621-9

Image Credits: AI Generated

DOI: 10.1186/s13071-026-07621-9

Keywords: Wolbachia, Dirofilaria immitis, heartworm, doxycycline, dogs, digital PCR, microfilariae, Rio de Janeiro, veterinary parasitology, macrocyclic lactones, endosymbiont, Parasites & Vectors